- Research works
- 79 ▲ 73% vs 2013–17
- Citations
- 1.1k 13.4 per fractional work
- Top-10% rate
- 9.2% record average 16.5%
- Open access
- 52% world 28%
Not ranked overall: Coherus BioSciences (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 14.3×. Every wedge is a field page.
- Immunology and Microbiology 14.3×
- Biochemistry, Genetics and Molecular Biology 4.4×
- Medicine 2.8×
- Nursing 1.5×
- Economics, Econometrics and Finance 1.5×
- Chemical Engineering 0.6×
- Chemistry 0.6×
- Materials Science 0.3×
- Pharmacology, Toxicology and Pharmaceutics 0.3×
- Neuroscience 0.2×
- Health Professions 0.2×
- Mathematics 0.1×
- Engineering 0.1×
- Agricultural and Biological Sciences 0.0×
- Computer Science 0.0×
- Environmental Science 0.0×
Who are the top researchers at Coherus BioSciences (United States)?
Ranked on the composite score, Martin Oft lead among researchers whose main affiliation is Coherus BioSciences (United States).
- 1 Martin Oft United States · #92,518 worldwide 295 citations · 29 works
Which keywords describe research at Coherus BioSciences (United States)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Tumor Microenvironment, Cancer, Chemotherapy, Monoclonal Antibodies, Immune Checkpoint Blockade, PD-1 and PD-L1, Cancer Therapy and Immunotherapy.
- Molecular Subtypes
- Leukemia
- Chimeric Antigen Receptor
- Tumor Regression
- Cetuximab
- Apoptosis
- Dendritic Cells
- Innate Immunity
- Antibody Engineering
- Glycosylation
- Febrile Neutropenia
- Hematological Malignancies
- Bioanalytical Methods
- Clinical Trials
- Immunity
- Cancer Immunotherapy
- Inflammation
- PD-1 and PD-L1
- Monoclonal Antibodies
- Cancer
- Tumor Microenvironment
- Chemotherapy
- Immune Checkpoint Blockade
- Cancer Therapy
- Immunotherapy
- Biopharmaceuticals
- Immunogenicity
- Therapeutic Antibodies
- Biosimilars
- Antimicrobial Agents
- Targeted Therapy
- Angiogenesis
- Fc Receptors
- Antigen Presentation
- Metabolism
- Activation
- Macrophage
- CAR T Cells
- Hematopoietic Stem Cells
- Lymphoma
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Tumor Microenvironment6▲ 33×7 topics
- Cancer5▲ 9.3×13 topics
- Chemotherapy5▲ 17×9 topics
- Monoclonal Antibodies4▲ 116×3 topics
- Immune Checkpoint Blockade3▲ 76×1 topic
- PD-1 and PD-L13▲ 76×1 topic
- Cancer Therapy3▲ 13×6 topics
- Inflammation3▲ 3.6×11 topics
- Immunotherapy3▲ 10×8 topics
- Cancer Immunotherapy3▲ 46×3 topics
- Biopharmaceuticals3▲ 132×3 topics
- Immunity3▲ 17×2 topics
- Immunogenicity2▲ 152×2 topics
- Clinical Trials2▲ 8.1×7 topics
- Therapeutic Antibodies2▲ 77×2 topics
- Bioanalytical Methods2▲ 253×1 topic
- Biosimilars2▲ 253×1 topic
- Hematological Malignancies2▲ 147×2 topics
- Antimicrobial Agents2▲ 276×1 topic
- Febrile Neutropenia2▲ 276×1 topic
- Targeted Therapy2▲ 19×5 topics
- Glycosylation2▲ 37×2 topics
- Angiogenesis2▲ 12×6 topics
- Antibody Engineering2▲ 70×1 topic
- Fc Receptors2▲ 70×1 topic
- Innate Immunity2▲ 12×2 topics
- Antigen Presentation1▲ 42×1 topic
- Dendritic Cells1▲ 41×1 topic
- Metabolism1▲ 7.2×4 topics
- Apoptosis1▲ 11×5 topics
- Activation1▲ 50×1 topic
- Cetuximab1▲ 36×2 topics
- Macrophage1▲ 42×1 topic
- Tumor Regression1▲ 27×2 topics
- CAR T Cells1▲ 39×1 topic
- Chimeric Antigen Receptor1▲ 39×1 topic
- Hematopoietic Stem Cells1▲ 33×2 topics
- Leukemia1▲ 35×2 topics
- Lymphoma1▲ 18×2 topics
- Molecular Subtypes1▲ 33×2 topics
Which research topics does Coherus BioSciences (United States) publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, Biosimilars and Bioanalytical Methods, Neutropenia and Cancer Infections and Monoclonal and Polyclonal Antibodies Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 2 Biosimilars and Bioanalytical Methods Immunology 2 works
- 3 Neutropenia and Cancer Infections Oncology 2 works
- 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 5 Immunotherapy and Immune Responses Immunology 1 works
- 6 Immune cells in cancer Immunology 1 works
- 7 Colorectal Cancer Treatments and Studies Oncology 1 works
- 8 CAR-T cell therapy research Oncology 1 works
- 9 Cancer-related Molecular Pathways Oncology 1 works
- 10 Blood disorders and treatments Genetics 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Coherus BioSciences (United States)'s research output changed?
Output in 2018–2022 was 73% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Redwood City
- Heron Therapeutics (United States)
- Chan Zuckerberg Initiative (United States)
- Emergency University
- Guardant (United States)
- Box (United States)
- OncoMed (United States)
- Genomic Health (United States)
- Ubiquitous Energy (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.